

Microfluidic preparation and characterization of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells

Ilaria Arduino,^{1,2} Zehua Liu,² Rosa Maria Iacobazzi,³ Angela Assunta Lopodota,¹ Antonio Lopalco,¹ Annalisa Cutrignelli,¹ Valentino Laquintana,¹ Letizia Porcelli,³ Amalia Azzariti,³ Massimo Franco¹, Helder A. Santos,^{2,4,*} and Nunzio Denora^{1,*}

¹Department of Pharmacy - Pharmaceutical Sciences, University of Bari “Aldo Moro”, Orabona St. 4, 70125, Bari, Italy

²Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland

³Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori "Giovanni Paolo II", O. Flacco St., 70124 Bari, Italy.

⁴Helsinki Institute of Life Science (HiLIFE), University of Helsinki, FI-00014 Helsinki, Finland

*** Corresponding authors:**

Nunzio Denora, Department of Pharmacy – Pharmaceutical Sciences, University of Bari “Aldo Moro”, Orabona St. 4, I-70125 Bari, Italy. (E-mail address: nunzio.denora@uniba.it)

Helder A. Santos, Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland. (E-mail address: helder.santos@helsinki.fi)

Abstract

Solid lipid nanoparticles (SLNs) can combine the advantages of different colloidal carriers and prevent some of their disadvantages. The production of nanoparticles by means of microfluidics represents a successful platform for industrial scale-up of nanoparticle manufacture in a reproducible way. The realisation of a microfluidic technique to obtain SLNs in a continuous and reproducible manner encouraged us to create surface functionalised SLNs for targeted drug release using the same procedure. A tumor homing peptide, iRGD, owning a cryptic C-end Rule (CendR) motif is responsible for neuropilin-1 (NRP-1) binding and for triggering extravasation and tumor penetration of the peptide. In this study, the Paclitaxel loaded-SLNs produced by microfluidics were functionalized with the iRGD peptide. The SLNs proved to be stable in aqueous medium and are characterized by a Z-average under 150 nm, a polydispersity index below 0.2, a zeta-potential between -20 and -35 mV and a drug encapsulation efficiency around 40%. Moreover, *in vitro* cytotoxic effects and cellular uptake have been assessed using 2D and 3D tumour models of U87 glioblastoma cell lines. Overall, these results demonstrate that the surface functionalization of SLNs with iRGD better cellular uptake and cytotoxicity ability.

Keywords

Solid lipid nanoparticles, microfluidics, iRGD peptide, 3D cell culture, targeted drug delivery, tumor cell.

1. Introduction

Solid lipid nanoparticles (SLNs) are very interesting colloidal systems that have been studied for almost twenty years (Paliwal et al. 2020). Like other nanoparticle systems, SLNs provide drug protection from degradation, sustained release and target-dependent biodistribution, but providing greater stability and more tolerability compared to other lipid formulations and polymeric systems (Arduino et al. 2021). In fact, the use of solid lipids in the preparation of SLNs greatly reduces the mobility of the drug loaded into the lipid matrix and protects it from clearance by the reticuloendothelial system (Becker Peres et al. 2016). Furthermore, their surface is easily modified for improving the circulation time in the blood stream and/or directing them to a specific target.

However, conventional methods to produce nanoparticles, and in this specific case SLNs, lead to the formation of nanoparticle systems with a wide size distribution and an evident batch-to-batch variability linked to the loss of control over the experimental variables (Arduino et al. 2021). For these reasons, an industrial scale-up to produce nanoparticles represents a challenge.

In recent years, microfluidics, an emerging technology enabling the manipulation of fluid (in nanoliters scale) in micrometer channels, has attracted a lot of interest in biomedical and pharmaceutical fields because it can be used to produce nano/micro-particles in a continuous process (Costa et al. 2020; Costa et al. 2021; Hussain et al. 2020; Liu, Zhang, et al. 2017; Liu et al. 2020). Microfluidics offers several advantages, including high batch-to-batch reproducibility, controlled manipulation of process parameters, thus providing the optimization and tunability of nanoparticles properties, including drugs encapsulation efficiency and monodispersity of batches (Martins et al. 2019). Polydimethylsiloxane (PDMS), glass and silica, are the common material used on the manufacturing of microfluidic devices. Among these different materials, glass is certainly the most suitable because it is cheap, inert towards organic solvents and it is easier to manufacture devices (Arduino et al. 2021).

Recently, we have developed the first set-up, known in literature, to produce SLNs by microfluidics (Arduino et al. 2021). We previously described the production of SLNs using glass-capillary microfluidic device through a systematic optimization process, opening a new avenue for the future standardization and scale-up of the production of such nanosystems. The achievement of a continuous and reproducible microfluidic method for the production of SLNs, prompted us to develop surface functionalized SLNs as targeted drug delivery system by using the same technique. SLNs can accumulate at tumour sites through the effect of enhanced permeability and retention (EPR) (Zheng et al. 2014), despite this, the design and microfluidics preparation of SLNs that could remain in blood circulation for longer time, also exploiting an active targeting to tumour sites is a very important

challenge. The presence of polyethyleneglycol (PEG) molecules to the nanoparticle surface enable prolonged circulation time, while the functionalization of their surface with specific targeting moieties can improve the tumour selectivity and therapeutic efficacy of the nanoparticle system in many solid tumours (Zheng et al. 2014).

Integrin receptors are cation-dependent heterodimeric cell adhesion molecules which play an important role in cell adhesion, cell signalling and angiogenesis. Overexpression of the $\alpha_v\beta_3$ integrin receptor has been widely observed in many forms of solid tumors (Garanti, A Alhnan, and Wan 2020). Specifically, the internalizing RGD peptide (iRGD, CRGDRGPDC) is a 9-aminoacid cyclic peptide that has a special structure, including a vascular homing motif RGD, a protease recognition site and a tumour cell targeting motif CendR (Lu et al. 2020; Sugahara et al. 2009). The iRGD peptide homes to tumours by acting in different stages. Initially, it binds to integrin $\alpha_v\beta_3$, which are expressed more on tumor cells and endothelial cells of tumour vessels (Liu, Jiang, et al. 2017; Ruoslahti and Pierschbacher 1987), then a tumor-derived protease cleavage exposes the CendR motif that is a binding site for neuropilin-1 NRP-1. NRP-1 binding leads to trigger endocytic transcytosis and trans-tissue transport pathway that can assist drug and nanoparticle delivery, increasing transcytosis efficiency and penetration level in solid tumors (Liu, Jiang, et al. 2017; Lu et al. 2020; Sugahara et al. 2010).

In this work, iRGD-functionalized SLNs (iRGD-SLN) and non-functionalized SLNs were developed by microfluidic technique. Paclitaxel (PTX), chosen as a model antitumor drug, was encapsulated within the produced SLNs. The iRGD-SLN system aimed to improve the anti-cancer potential of PTX by providing its selective delivery to cancer cells and increased accumulation and penetration into tumor site. SLNs were firstly characterized for their size and size distribution, drug encapsulation efficiency and drug release profile. Then, *in vitro* cell viability studies were conducted on human glioblastoma U87-MG cells overexpressing $\alpha_v\beta_3$ integrin receptor, in order to demonstrate the better efficacy of the PTX formulated in a targeted NPs system (iRGD-SLN-PTX) respect to PTX used as such. Moreover, the internalization studies of the targeted iRGD-SLN were conducted both in 2D and 3D *in vitro* models of human glioblastoma U87-MG cells by means of flow cytometric analysis and fluorescence imaging.

2. Materials and methods

2.1. Materials

All chemicals were of the highest purity available and were used as received without further purification or distillation. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-

[maleimide(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG-maleimide) was purchased from Avanti Polar Lipids. Cetyl palmitate was purchased from Farmalabor. Paclitaxel (PTX), Pluronic F68 and Tween 80 were purchased from Sigma Aldrich. All solvents used were of analytical grade and purchased from Aldrich. The iRGD (CCRGDKGPDC) was purchased from GenicBio. iRGD with a fluorescein isothiocyanate (FITC) was acquired from United BioSystem Inc. Bodipy alkyne dye (BDP) was acquired from Lumiprobe GmbH (Germany). All aqueous solutions were prepared using water obtained from a Milli-Q gradient A-10 system (Millipore, 18.2 M Ω ·cm, organic carbon content \geq 4 μ g/L). Dulbecco's Modified Eagle's medium (DMEM), heat inactivated fetal bovine serum (FBS), L-glutamine (200 mM), non-essential amino acids (NEAA), penicillin (100 IU/mL), streptomycin (100 mg/mL) and trypsin (2.5%) were acquired from HyClone Waltham, USA. Phosphate buffer saline (10XPBS) and Hank's balanced salt solution (10 \times HBSS) were purchased from Hyclone. Disposable culture flasks and Petri dishes were from Corning (Glassworks).

2.2. Preparation of glass capillary microfluidic chip

The microfluidic devices were assembled from borosilicate glass capillaries and glass rods. One end of the cylindrical glass capillary (World Precision Instruments, Inc.), with inner and outer diameters of 580 and 1000 μ m, respectively, was tapered using a micropipette puller (P-97, Sutter Instrument Co., USA) to a diameter of 20 μ m; this diameter was further enlarged to approximately 80 μ m by using sandpaper (RHYNOWET P-2500, Indasa, USA). This cylindrical tapered capillary was inserted and coaxially aligned into the left end of the cylindrical capillary with inner dimension of 1100 μ m (Vitrocom, USA) and a three-port valve is connected after the device (Arduino et al. 2021). Two miscible (functioning as outer and inner phase for nanoparticle production) liquids were injected separately into the microfluidic device through polyethylene tubes attached to syringes at constant flow rates, and the air was introduced to the solution through the three-port valve to further enhance the mixing efficiency. The flow rate of the different liquids was controlled by pumps (PHD 2000, Harvard Apparatus, USA). During the production of SLNs, it was fundamental to keep the temperature above 60 $^{\circ}$ C. In this regard, a supporting heating facility was designed and constructed by wrapping the lipid containing syringe with electric wire, which connected with a pressure regulator; the temperature of the electric wire wrapped syringe was controlled by altering the voltage, and the temperature was set to 60 $^{\circ}$ C. The microfluidic chip was immersed in water containing heating bath, and the temperature was also maintained at 60 $^{\circ}$ C.

2.3. Preparation of solid lipid nanoparticles by microfluidic technique

The SLNs were prepared by nanoprecipitation in a glass capillary microfluidics device (Arduino et al. 2021). The co-flow geometry is the main geometry for producing nanoparticles. In co-flow geometry, the fluids of the inner and the outer flow in parallel streams. The organic phase consisted of a mixture of 10 mg/mL of Cetil Palmitate and 3 mg/mL of DSPE-PEG-maleimide, containing 0.75 mg/mL of PTX. The aqueous phase consisted of 2% (w/v) of Pluronic F68. The organic and aqueous phase corresponded to the inner and outer fluid, respectively. With the usage of two microfluidics pumps, we set the flow rate of the inner (10 mL/min) and the outer solution (50 mL/min) and we kept the flow-rate constant. The liquids flowed from their respective syringes into the devices through tiny tubes. To remove the surfactant and non-encapsulated drug, the produced SLNs were carefully purified using centrifugal concentrators (Centrifugal Filter Units-Amicon Ultra 100k) by ultrapure water at 4 °C, 3500 rpm for 15 min (5 times). Finally, the purified SLNs were stored at 4 °C.

2.4. Functionalization of Solid Lipid Nanoparticles with iRGD peptide

SLNs were functionalized with iRGD peptide, through the maleimide thiol reaction. Namely, the conjugation of iRGD peptide onto preformed robust SLNs, based on the effortless binding between the thiol in iRGD peptide and the maleimide group on the SLNs surface. Briefly, 50 µL of iRGD peptide (1 mg/mL) was added to 2 mL of the SLNs suspension and incubated for 1 h at room temperature. The pH of the reaction was kept between 6.5-7.5, to ensure that the maleimide reacted with the sulphhydryl group of the peptide. The double bound of the maleimide reacted with the thiol group on the cysteine of the peptide to form a stable carbon-sulfur bond. The reaction resulted on the formation of a not reversible tioether bond. To remove the non-bonded peptide, the functionalized SLNs were carefully purified using centrifugal concentrators (Centrifugal Filter Units-Amicon Ultra 100k) by ultrapure water at 4 °C, 3500 rpm for 15 min (5 times). Finally, they were stored at 4 °C.

2.5. Evaluation of Drug Encapsulation Efficiency

The percentage of encapsulation efficiency (EE, %) of PTX inside the SLNs were evaluated using the HPLC (Agilent 1 260, Agilent Technologies, USA). Shortly, 200 µL of SLNs were freeze-dried and after being dissolved with 1 mL acetonitrile, 20 µL of the resulting solution were injected into HPLC. For the HPLC detection was used a Discovery C₁₈ column (15 cm × 4.6 mm, 5 µm) and the mobile phase consisted of water and acetonitrile (48:52) with detection at 227 nm. Drug encapsulation efficacy was calculated using Eq. (1):

$$\text{Encapsulation Efficacy (\%)} = \frac{\text{Weight of drug in SLN}}{\text{Weight of drug added initially}} \times 100 \quad (1)$$

2.6. Particle size, size distribution and surface charge

After preparation, the nanoparticles were characterized by dynamic light scattering to obtain information about their size, polydispersity index (PDI), and zeta (ζ)-potential, using Malvern Zetasizer Nano instrument (Malvern Ltd., UK). About 1 mL of a 1:100 dilutions of each sample with demineralized water, was pipetted into a disposable polystyrene cuvette (Sarstedt AG & Co., Germany) and the measurements were carried out at 25 ± 0.1 °C. The surface ζ -potential of the nanoparticles was measured by pipetting 750 μ L of each particle suspension into a disposable folder capillary cell (DTS1070, Malvern, UK); all samples were redispersed in MillQ-water (pH 7.4) before assessing their surface potential. The results are shown as numeric average and standard deviation of the measurements of 3 different samples, each sample measured 3 times.

2.7. Estimation of peptide quantity on the solid lipid nanoparticles

iRGD with a fluorescein isothiocyanate (FITC) group was conjugated onto SLNs by the same reaction of iRGD-SLNs fabrication described above. Then, 1 mg/mL FITC-iRGD-SLNs were solubilized by 0.5% Triton-100 to ensure FITC was not being quenched and subjected to fluorescence detection. A standard curve of free FITC-iRGD was used to calculate the molar concentration of FITC-iRGD in SLNs samples.

2.8. In vitro drug release study

Studies of PTX release from SLNs were conducted using Franz cells, and experiments were performed in presence and absence of lipase from porcine in the donor compartment. Briefly, 500 μ L of SLN-PTX was diluted with 500 μ L of water or lipase (1 mg/mL in water) and placed on the diffusion barrier (area of 0.6 cm²) constituted by an artificial cellulose acetate membrane (1 kDa, Fisher Scientific Milano), which divides donor and receptor cells. Phosphate buffer (PBS, 10 mM, pH 7.4) with 1% (w/v) of Tween 80 was chosen as receptor medium and it was constantly stirred and preserved at a temperature of (37 ± 0.5 °C). In an overall time of 72 h, 0.2 mL was picked up from the receiving compartment at set times, and to provide the sink conditions the equivalent volume of refreshing PBS was included in the receptor cell. The collected fractions were analyzed by HPLC to determine the drug content. Each experiment was performed in triplicate and was conducted in three separate Franz cells using three distinct batches of SLNs.

2.9. Cell Culture

Human glioblastoma U87-MG cells were purchased from American Type Culture Collection (ATCC, VA, USA) and were cultured as previously reported (Arduino et al. 2021).

For U87-MG tumour spheroids formation, cells were seeded at a density of 5000 cells per well on 96-well plate Corning® Spheroid Microplate and incubated at 37 °C under 5% CO₂ for 5 days before performing experiments. Spheroid formation was assessed using OLYMPUS CKX41 microscope. (OLYMPUS, Tokyo, Japan)

2.10. *In vitro* cytotoxicity study

In order to perform the *in vitro* cytotoxicity study, U87-MG cells were seeded in 96-well plates (PerkinElmer Inc., USA) at a density of 5000 cells per well and left attaching overnight before performing the assay. Afterward, cells were treated for 24 h at 37 °C with suspensions in DMEM of empty SLNs (SLN), PTX loaded SLNs (PTX-SLN) and of targeted PTX loaded SLNs (iRGD-PTX-SLN) at different concentrations in terms of nanoparticles (25, 50, 100, 250, 500 and 1000 µg/mL), and then washed out and cultured in fresh medium up to 72 h by the start of the experiment. Cells treated with solutions of free PTX at concentrations corresponding to those loaded in SLNs (0.275, 0.55, 1.1, 5.5, 11, 22 µg/mL) were used as reference. After that, the plates were equilibrated at room temperature for 30 min and the wells were washed once with 100 µL of HBSS–HEPES buffer. Then, 50 µL of Cell Titer-Glo (Promega Corporation, USA) were added to 50 µL of HBSS–HEPES (pH 7.4) in each well. The plates were stirred for 2 min on an orbital shaker and then stabilized for 30 min at room temperature, protected from the light. Finally, the luminescence was measured using a Victor™ X3 (WALLAC Oy, Turku, Finland by PerkinElmer Singapore) plate reader. The number of viable cells was quantified based on the amount of ATP produced by metabolically active cells. Data were plotted as % cell viability, normalized vs untreated cells, registered for each tested concentration.

2.11. *In vitro* uptake study on 2D and 3D model of glioblastoma

The internalization studies of the targeted iRGD-SLN were conducted *in vitro* both in 2D and 3D models of human glioblastoma U87-MG cells by means of flow cytometric analysis and fluorescence imaging. For these experiments, iRGD-functionalized and non-functionalized SLNs were loaded with the fluorescent dye BODIPY (BDP).

For the uptake experiment in 2D, according to a protocol described in Iacobazzi *et al.* (Iacobazzi *et al.* 2017), U87-MG cells were seeded in 6-well plates (Corning®) at a density of 300000 cells per well and after attachment were incubated at 37 °C and at 4 °C (for external binding detection), for 2 h with the targeted iRGD-BDP-SLN and for comparison with the no targeted BDP-SLN, at a concentration of 0.01 µM in terms of the loaded fluorescent dye (BDP). Then, cells were maintained at 4 °C for the rest of the experiment, detached with trypsin-EDTA, washed with cold PBS, and finally re-suspended in PBS without Ca²⁺ and Mg²⁺. The cell-internalized fluorescence was measured by flow-cytometry on AttuneNxT acoustic focusing cytometer (Life Technologies). 10000 events were counted in the viable gate and the geometric mean of the viable cell population exposed to SLNs compounds was used to determine their internalization, after correction for cell auto-fluorescence and for SLNs compounds-autofluorescence. In particular, the amount of internalized SLNs was calculated subtracting 4 °C values from 37 °C values. Data were interpreted using the CytExpert software v.1.1.2, provided by the manufacturer and represent mean ± SD, n=3.

For the competition study, cells were pre-incubated for 30 min with excess of iRGD (5µM) prior the addition of the targeted iRGD-BDP-SLN. After the incubation time, cells were processed as described above and the cell-associated fluorescence measured by flow-cytometry.

The qualitative analysis of the uptake was performed on 3D model of U87-MG cells allowed to generate spheroids on 96 well plate Corning® Spheroid Microplate for 5 days. After incubation for 2 h with iRGD-BDP-SLN and bare SLN-BDP and for 30 minutes with Hoechst 33342 dye (2 µg/mL, Invitrogen™) for nucleic acid staining, spheroids were washed and recovered with PBS without Ca²⁺ and Mg²⁺ and finally visualized on Celldiscoverer 7 microscope (Carl Zeiss Microscopy, Germany), with a Plan-Apochromat 20×/0.95 objective and optavar 0.5x tubelens. The competition study was also conducted in the 3D model, as described above.

2.12. Statistical analysis

Results were expressed as mean ± SD from three independent experiments and analyzed using GraphPad Prism *vers* 5.0 to calculate the significance between groups using paired Students's *t*-test method (two-tailed). A difference was considered to be very significant with *** $p < 0.0001$. For cell viability test statistical significance was calculated using a two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc tests (GraphPad Prism *vers* 5.0). Statistically significant differences are set at probabilities of * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

3. Results and discussion

3.1. Preparation and characterization of solid lipid nanoparticles

The production of SLNs by microfluidics was carried out for the first time by our research group (Arduino et al. 2021). Through a process of optimisation of several parameters, the best conditions to produce SLNs with small size, narrow size distribution and good encapsulation efficiency were achieved. SLNs are produced in a single continuous step through a microfluidic chip based on glass capillaries. The use of microfluidics technology achieved high yield, good reproducibility, and precise control over the physical properties of SLNs, which are critical pre-conditions for its successful industrialization. In this work, SLNs loaded with PTX were produced by microfluidic technique and subsequently functionalised with the iRGD peptide (Figure 1).

<<Insert Figure 1>>

The SLNs were fully characterized, and the results are shown in Table 1. SLN-PTX presented an average size of 136.3 ± 3.1 nm and a PdI of 0.101 ± 0.03 , whereas SLNs without PTX presented an average size of 124.4 ± 2.7 and a PdI of 0.155 ± 0.023 . Production by microfluidics provided SLNs with a narrow distribution range, which is indicated by a low PdI, the slight increase in size in SLN-PTX was ascribed to the PTX loaded within the nanosystem.

Table 1. Intensity-average hydrodynamic diameter and corresponding PdI determined by DLS, ζ -potential value, drug encapsulation efficiency (EE, %) of all prepared SLNs.

Nanoformulation	d_{mean} (nm)	Polydispersity index (PdI)	ζ - potential(mV)	Encapsulation Efficiency(EE%)
SLN	124.4 ± 2.7	0.155 ± 0.023	-36.8 ± 1.2	-
SLN-PTX	136.3 ± 3.1	0.101 ± 0.037	-31.1 ± 0.8	40.4 ± 6.8
iRGD-SLN	142.7 ± 2.9	0.205 ± 0.020	-21.8 ± 1.9	-
iRGD-SLN-PTX	137.3 ± 2.5	0.279 ± 0.013	-11.2 ± 3.3	31.7 ± 4.8

Mean \pm SD are reported, n=3

As shown in our previous work, to produce SLNs with a size around 100 nm the flow rate ratio employed was 1:5, demonstrating that an increase in the flow rate ratio resulted in an effective improvement in mixing (Arduino et al. 2021). In fact, as reported in the literature and in agreement with our work, the flow rate ratio influences the size of the nanoparticles (Jahn et al. 2010; Maeki et al. 2015). In addition, the size reduction was achieved by employing a microfluidic device connected to a three-port valve, which through a continuous pumping of air, improved the mixing (Arduino et al. 2021). The ζ -potential measurements highlighted the presence of an overall negative charge on

the surface of all SLNs and provided values ranging from -11.2 to -36.8 mV. The bare SLNs obtained a ζ -potential value of -36.8 ± 1.2 mV, similarly to the SLN-PTX that showed -31.1 ± 0.8 mV. However, the ζ -potential of SLNs increased after conjugation with iRGD to -21.8 ± 1.9 and -11.2 ± 3.3 mV, respectively. This suggested that the functionalization of the SLNs with iRGD peptide occurred effectively, due to the decreased amount of maleimide groups on the SLNs' surface and the overall charge of the side chains of the peptide.

The SLNs were also prepared using a PEG modified phospholipid, which allowed the binding with iRGD peptide by its maleimide group, but also the function of reducing the opsonization of SLNs and the uptake by the endothelial reticular system (Arduino, Iacobazzi, et al. 2020). In particular, iRGD was conjugated to the maleimide group of DSPE-PEG-maleimide through maleimide-thiol reaction as already described (Wang et al. 2014; Yan et al. 2016). It is well documented in the literature that iRGD peptide can promote the penetration and tumour cell entry of a range of therapeutics in multiple cancer types (Liu, Jiang, et al. 2017; McNeil 2016; Sugahara et al. 2010). For example, through the iRGD conjugation on 230 nm doxorubicin loaded liposomes, the authors successfully demonstrated facilitated cellular uptake of liposomes and an ~ 2 -fold enhanced antitumor effect in a subcutaneous breast cancer (4T1) model (Liu et al. 2013). Furthermore, Garanti *et al.* demonstrated the higher cell death and the greater uptake of the iRGD-SLNs toward U87 MG cells confirmed the potential of using this targeting strategy for the treatment of glioblastoma (Garanti, A Alhnan, and Wan 2020). To estimate the concentration of peptide on the iRGD-SLNs, a fluorescent peptide FITC-iRGD was conjugated and the fluorescence of the resultant FITC-iRGD-SLNs was assessed. By comparison to a fluorescent standard curve of free FITC-iRGD, it was calculated that 1 mg/mL of iRGD-SLNs contained an average of 20 μ M of peptide. For all the SLNs, the EE (%) values represent the amount (w/w, %) of the drug incorporated in the lipid core of SLNs with respect to the starting drug amount employed for the preparation of lipid nanovectors. The EE (%) values were 40.4 ± 6.8 % and 31.7 ± 4.8 % for SLN-PTX and iRGD-SLN-PTX, respectively.

In vitro drug release study was performed on SLN-PTX using Franz-diffusion cells at 37 °C in PBS (pH 7.4). As reported in the literature, SLNs are highly stable systems, and several studies have revealed that drug release from the lipid matrix occurs following degradation by enzymes in the cell (Arduino, Depalo, et al. 2020; Arduino, Iacobazzi, et al. 2020). The degradation velocity of SLNs depend on the nature of the lipid matrix, thus the *in vitro* release study, was conducted in presence of lipase in the donor compartment.

<<Insert Figure 2>>

The drug release profiles shown in Figure 2 indicated that PTX loaded SLNs exhibited sustained drug release behaviour. In the absence of lipase, SLNs released about 10 % of PTX in 6 h, reaching 20 % in 8 h and maintaining this percentage until 24 h. Instead, in the presence of lipase, SLNs released about 35 % of PTX in the first 6 h, 50 % in 24 h and finally 100 % in 72 h.

3.2. Cell viability studies

The cell viability studies were performed on human glioblastoma U87-MG cells monolayer with a recovery from treatment protocol to assess the efficacy of the PTX formulated in a targeted nanoparticles system (iRGD-SLN-PTX) respect to PTX used as such. For comparison, no targeted SLN-PTX and the empty targeted iRGD-SLN were tested to understand the intrinsic cytotoxicity of the carrier. As shown in Figure 3, empty iRGD-SLN were no cytotoxic, whereas PTX showed a concentration dependent cellular toxicity manner. However, iRGD-PTX-SLN showed the overall better anticancer efficiency comparing to free PTX, where at the PTX concentration of 11 $\mu\text{g/mL}$, iRGD-PTX-SLN showed significantly higher toxicity comparing to bare SLN-PTX ($67\pm 6\%$ vs. $77\pm 3\%$), and free PTX ($67\pm 6\%$ vs. $84\pm 6\%$), confirming the enhanced cytotoxic effect of the targeted iRGD-PTX-SLN.

<<Insert Figure 3>>

3.3. In vitro uptake study

The preferential uptake of the targeted iRGD-SLN into U87-MG cells overexpressing $\alpha_v\beta_3$ receptor (Garanti, A Alhnan, and Wan 2020) was quantitatively assessed by flow cytometric analysis conducted on U87-MG cells samples, obtained as described in the experimental section after incubation at 37 °C and 4°C for 2 h with iRGD-BDP-SLN and for comparison with the bare BDP-SLN. Flow cytometry studies (Figure 4a, b) quantitatively confirmed that targeted iRGD-BDP-SLN (amount of internalized fluorescence: 22160 ± 500) were significantly more internalized by the cells respect to no targeted system BDP-SLN (amount of internalized fluorescence: 15488 ± 550). This trend could be explained with the positive involvement of the receptor-mediated uptake strategy for targeted SLNs, confirmed by the competition study (Figure 4c, 4d). In fact, when cells were pre-incubated with iRGD before the addition of iRGD-BDP-SLN, the amount of internalized fluorescence was significantly lower (2352 ± 127), confirming that targeted SLN exploited both the passive endocytic and the receptor mediated pathways of cell internalization.

<<Insert Figure 4>>

Moreover, uptake and competition studies were conducted also on tumour spheroids of U87-MG cells to assess qualitatively the ability of iRGD-SLN to penetrate even a more complex structure than a 2D cell monolayer. As clearly evidenced by the fluorescence imaging pictures acquired by Celldiscoverer 7 microscope, the fluorescence intensity of iRGD-BDP-SLN (Figure 5, panel a) displayed a more homogeneous intracellular localization throughout the spheroid, even in the core, as evidenced by the colocalization of the red signal related to the BDP-charged nanoparticles with the Hoechst dye staining for nuclei, unlike the no target BDP-SLN, which appeared predominantly at the edges of the spheroids (Figure 5, panel b).

Furthermore, the images related to the 3D competition study also confirmed a clear reduction of internalized fluorescence from the spheroid when it was pre-incubated and co-incubated with iRGD in addition to the iRGD-BDP-SLN (Figure 5, panel c).

<<Insert Figure 5>>

4. Conclusions

In this work, the microfluidic technique was used to produce SLNs. Here we showed the parameters to manufacture SLNs and their later functionalization with the iRGD peptide. iRGD-SLN have enhanced the anticancer activity of PTX by increasing cytotoxicity and providing more efficient tumour targeting and penetration both in 2D and 3D models U87-MG cells. Overall, these results demonstrate that the surface functionalization of SLNs with iRGD i cellular improves uptake and cytotoxicity ability. Furthermore, the investigated antitumor effects detected with the iRGD-SLN might also be potentially employed to other forms of cancers where integrin is associated.

Acknowledgements

H. A. S. acknowledges HiLIFE Research Funds, the Sigrid Jusélius Foundation, and the Academy of Finland (Grants No. 317042 and 331151)) for financial support.

References

- Arduino, I., R. M. Iacobazzi, C. Riganti, A. A. Lopodota, M. G. Perrone, A. Lopalco, A. Cutrignelli, M. Cantore, V. Laquintana, M. Franco, N. A. Colabufo, G. Luurtsema, M. Contino, and N. Denora. 2020. 'Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease', *Int J Pharm*, 591: 120011.
- Arduino, I., Z. Liu, A. Rahikkala, P. Figueiredo, A. Correia, A. Cutrignelli, N. Denora, and H. A. Santos. 2021. 'Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique', *Acta Biomater*, 121: 566-78.
- Arduino, Ilaria, Nicoletta Depalo, Francesca Re, Roberta Dal Magro, Annamaria Panniello, Nicola Margiotta, Elisabetta Fanizza, Antonio Lopalco, Valentino Laquintana, Annalisa Cutrignelli, Angela Assunta Lopodota, Massimo Franco, and Nunzio Denora. 2020. 'PEGylated solid lipid nanoparticles for brain delivery of lipophilic kiteplatin Pt(IV) prodrugs: An in vitro study', *International Journal of Pharmaceutics*, 583: 119351.
- Becker Peres, Luana, Laize Becker Peres, Pedro Henrique Hermes de Araújo, and Claudia Sayer. 2016. 'Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique', *Colloids and Surfaces B: Biointerfaces*, 140: 317-23.
- Costa, Clarinda, Zehua Liu, João P. Martins, Alexandra Correia, Patrícia Figueiredo, Antti Rahikkala, Wei Li, Jani Seitsonen, Janne Ruokolainen, Sami-Pekka Hirvonen, Ana Aguiar-Ricardo, M. Luísa Corvo, and Hélder A. Santos. 2020. 'All-in-one microfluidic assembly of insulin-loaded pH-responsive nano-in-microparticles for oral insulin delivery', *Biomaterials Science*, 8: 3270-77.
- Costa, Clarinda, Zehua Liu, Sandra I. Simões, Alexandra Correia, Antti Rahikkala, Jani Seitsonen, Janne Ruokolainen, Ana Aguiar-Ricardo, Hélder A. Santos, and M. Luísa Corvo. 2021. 'One-step microfluidics production of enzyme-loaded liposomes for the treatment of inflammatory diseases', *Colloids and Surfaces B: Biointerfaces*, 199: 111556.
- Garanti, Tanem, Mohamed A Alhnan, and Ka-Wai Wan. 2020. 'RGD-decorated solid lipid nanoparticles enhance tumor targeting, penetration and anticancer effect of asiatic acid', *Nanomedicine*, 15.
- Hussain, M. T., M. Tiboni, Y. Perrie, and L. Casettari. 2020. 'Microfluidic production of protein loaded chimeric stealth liposomes', *Int J Pharm*, 590: 119955.
- Iacobazzi, R. M., L. Porcelli, A. A. Lopodota, V. Laquintana, A. Lopalco, A. Cutrignelli, E. Altamura, R. Di Fonte, A. Azzariti, M. Franco, and N. Denora. 2017. 'Targeting human liver cancer cells

- with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers', *Int J Pharm*, 528: 485-97.
- Jahn, Andreas, Samuel M. Stavis, Jennifer S. Hong, Wyatt N. Vreeland, Don L. DeVoe, and Michael Gaitan. 2010. 'Microfluidic Mixing and the Formation of Nanoscale Lipid Vesicles', *ACS Nano*, 4: 2077-87.
- Liu, Dongfei, Hongbo Zhang, Salvatore Cito, Jin Fan, Ermei Mäkilä, Jarno Salonen, Jouni Hirvonen, Tiina M. Sikanen, David A. Weitz, and Hélder A. Santos. 2017. 'Core/Shell Nanocomposites Produced by Superfast Sequential Microfluidic Nanoprecipitation', *Nano Letters*, 17: 606-14.
- Liu, Xiangsheng, Jinhong Jiang, Ying Ji, Jianqin Lu, Ryan Chan, and Huan Meng. 2017. 'Targeted drug delivery using iRGD peptide for solid cancer treatment', *Molecular systems design & engineering*, 2: 370-79.
- Liu, Yarong, Man Ji, Michael K. Wong, Kye-Il Joo, and Pin Wang. 2013. 'Enhanced Therapeutic Efficacy of iRGD-Conjugated Crosslinked Multilayer Liposomes for Drug Delivery', *BioMed Research International*, 2013: 378380.
- Liu, Zehua, Flavia Fontana, Andre Python, Jouni T. Hirvonen, and Hélder A. Santos. 2020. 'Microfluidics for Production of Particles: Mechanism, Methodology, and Applications', *Small*, 16: 1904673.
- Lu, Lu, Xiaojing Zhao, Tiwei Fu, Ke Li, Ye He, Zhong Luo, Liangliang Dai, Rui Zeng, and Kaiyong Cai. 2020. 'An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy', *Biomaterials*, 230: 119666.
- Maeki, Masatoshi, Tatsuyoshi Saito, Yusuke Sato, Takao Yasui, Noritada Kaji, Akihiko Ishida, Hirofumi Tani, Yoshinobu Baba, Hideyoshi Harashima, and Manabu Tokeshi. 2015. 'A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer structure', *RSC Advances*, 5: 46181-85.
- Martins, Cláudia, Francisca Araújo, Maria João Gomes, Carlos Fernandes, Rute Nunes, Wei Li, Hélder A. Santos, Fernanda Borges, and Bruno Sarmiento. 2019. 'Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy', *European Journal of Pharmaceutics and Biopharmaceutics*, 138: 111-24.
- McNeil, Scott E. 2016. 'Evaluation of nanomedicines: stick to the basics', *Nature Reviews Materials*, 1: 16073.
- Paliwal, Rishi, Shivani Rai Paliwal, Rameshroo Kenwat, Balak Das Kurmi, and Mukesh Kumar Sahu. 2020. 'Solid lipid nanoparticles: a review on recent perspectives and patents', *Expert Opinion on Therapeutic Patents*, 30: 179-94.

- Ruoslahti, E., and M. D. Pierschbacher. 1987. 'New perspectives in cell adhesion: RGD and integrins', *Science*, 238: 491-7.
- Sugahara, K. N., T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, O. M. Girard, D. Hanahan, R. F. Mattrey, and E. Ruoslahti. 2009. 'Tissue-penetrating delivery of compounds and nanoparticles into tumors', *Cancer Cell*, 16: 510-20.
- Sugahara, Kazuki N., Tambet Teesalu, Priya Prakash Karmali, Venkata Ramana Kotamraju, Lilach Agemy, Daniel R. Greenwald, and Erkki Ruoslahti. 2010. 'Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs', *Science*, 328: 1031-35.
- Wang, K., X. Zhang, Y. Liu, C. Liu, B. Jiang, and Y. Jiang. 2014. 'Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates', *Biomaterials*, 35: 8735-47.
- Yan, F., H. Wu, H. Liu, Z. Deng, H. Liu, W. Duan, X. Liu, and H. Zheng. 2016. 'Molecular imaging-guided photothermal/photodynamic therapy against tumor by iRGD-modified indocyanine green nanoparticles', *J Control Release*, 224: 217-28.
- Zheng, J., Y. Wan, A. Elhissi, Z. Zhang, and X. Sun. 2014. 'Targeted paclitaxel delivery to tumors using cleavable PEG-conjugated solid lipid nanoparticles', *Pharm Res*, 31: 2220-33.